RemeGen Co. Ltd.SSE: 688331

Indicative Announcement on Obtaining Term Compensation for Core Drug Patent

Jun 14, 2025 · Issued by RemeGen Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Jun 14, 2025

On 6ix: 6ix.com/news/indicative-announcement-on-obtaining-term-compensation-for-core-drug-patent

Indicative Announcement on Obtaining Term Compensation for Core Drug Patent

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

RemeGen Co. Ltd. on 6ix

Earlier from RemeGen

2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric CancerJun 2, 2025
Announcement on Completing the Issuance of H SharesMay 30, 2025
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in ChinaMay 27, 2025
Notice on Convening the 2024 Annual General Meeting, the 1st A-share General Meeting of 2025, and the 1st H-Share General Meeting of 2025May 27, 2025
Announcement on Reply to Letter of Regulatory Inquiry from Shanghai Stock ExchangeMay 24, 2025

Later from RemeGen

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia GravisJun 17, 2025
Announcement on Resolutions of the 2024 Annual General Meeting, the 1st A-Share Shareholders' Meeting and the 1st H-Share Shareholders' Meeting in 2025Jun 27, 2025
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDAAug 8, 2025
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in ChinaAug 13, 2025
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countriesAug 19, 2025

All RemeGen news releases

Follow RemeGen into a list and get an email when it puts out news.

Follow RemeGen